Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • (Business Wire India; 10th July, 2014); Celgene Corporation (NASDAQ:CELG) announced results of its phase III POSTURE study evaluating OTEZLA, the company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with active ankylosing spondylitis. The OTEZLA arms did not achieve statistically significant improvement versus the placebo arm for the primary endpoint, the percentage of patients who achieve an ASAS (Assessment of SpondyloArthritis international Society) 20 response at week 16. However, in a prespecified analysis, meaningful efficacy was observed at Week 24 in a large subset of patients with early-stage disease. Evaluation of the efficacy results is ongoing.

    [adsense:336x280:8701650588]

  • (3rd July, 2014); Four new vaccines are introduced as part of India’s Universal Immunization Programme (UIP), announced by Shri Narendra Modi, Prime Minister of India. Vaccines against rotavirus, rubella and polio (injectable) will collectively expedite India’s progress on meeting the Millennium Development Goal 4 targets to reduce child mortality by two-thirds by the year 2015 and meet global polio eradication targets. In addition, an adult vaccine against Japanese encephalitis will be introduced in districts with high levels of the disease.

  • Health Minister discussed Indian health system & scenarios at Centre for Disease Control and Prevention, Atlanta
    30 June 2014
    Health Minister discussed Indian health system & scenarios at Centre for Disease Control and Prevention, Atlanta

    (30th June, 2014); Union Health Minister Dr. Harsh Vardhan held a four hour long meeting with top experts at the world famous Centre for Disease Control and Prevention (CDC) at Atlanta on 28th June.

  • BGS Global Hospitals Performs the 1st Dual Organ Transplantation in Karnataka
    30 June 2014
    BGS Global Hospitals Performs the 1st Dual Organ Transplantation in Karnataka

    (Business Wire India; 30th June, 2014); BGS Global Hospitals, Super Specialty Tertiary Care,  on the eve of doctor’s day, organized a press conference on the 1st successful Combined Dual Organ (Liver and Kidney) Transplantation procedure in Karnataka.

  • Type 2 Diabetes: Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials
    20 June 2014
    Type 2 Diabetes: Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials

    (20th June, 2014); Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in adults with Type 2 Diabetes (T2D) at the American Diabetes Association's 74th Scientific Sessions®. Results showed that empagliflozin in combination with certain other diabetes therapies reduced blood glucose, body weight and blood pressure.

  • (Business Wire India; 20th June, 2014); Boehringer Ingelheim today announces a new study of Pradaxa® (dabigatran etexilate) in patients with atrial fibrillation (AF). The RE-CIRCUIT™ study will investigate the safety and efficacy of uninterrupted anticoagulant treatment with Pradaxa® in patients with AF who undergo ablation. Results of the study are expected in 2016.

    [adsense:336x280:8701650588]

Subscribe to Pharma News